Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
12-Sep-2019
MTD achieved in St Jude study in DIPG
4-Sep-2019
Change in Directors interests - James Garner
29-Aug-2019
Kazia Annual Report to shareholders
29-Aug-2019
Kazia Appendix 4E
23-Aug-2019
WHO selects provisional name for Kazia's GDC-0084
13-Aug-2019
Kazia completes recruitment to Cantrixil Phase 1 trial
22-Jul-2019
Kazia collaboration with MSK
10-Jul-2019
Substantial shareholder change in interests
3-Jul-2019
Appendix 3Y for 4 directors
3-Jul-2019
Change in substantial shareholder interest
Previous
1
2
3
4
5
6
Next
